Article
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $118 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $118 price target.
Comments
- No comments yet. Be the first to comment!